Exact Sciences to Participate in December Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Leerink Partners on Exact Sciences (EXAS): 'Cologuard Plus Pricing Higher vs. Expectations; EXAS Unlikely to Pursue ADLT'
November 26, 2024 7:17 AM ESTLeerink Partners analyst Puneet Souda reiterated an Outperform rating and $70.00 price target on Exact Sciences (NASDAQ: EXAS)
The analyst comments "Bottom Line: This evening, CMS released finalized clinical lab fee schedules (CLFS) determinations that were a clear positive for EXAS (OP). The company was able to secure Medicare pricing of $592 for its next-gen assay Cologuard Plus (CG+) that is launching in late 1Q/early 2Q. The Medicare pricing is 16% higher vs. current Medicare rate of $509 for current Cologuard. We would expect EXAS shares to be up tomorrow, after being down 23%... More
Bernstein SocGen Group Reiterates Outperform Rating on Exact Sciences (EXAS)
November 26, 2024 7:16 AM ESTBernstein SocGen Group analyst Eve Burstein reiterated an Outperform rating and $70.00 price target on Exact Sciences (NASDAQ: EXAS).
The analyst comments "On Monday afternoon Medicare released its final 2025 clinical laboratory fee schedule, which includes a ~16% increase in contracted rate for Cologuard Plus vs. current Cologuard. The rate crosswalks Cologuard Plus to 3x the contracted rate for Epi proColon ($192 x 3), plus 1x the rate for FIT ($15.92). Together, this new contracted rate of $591.92 is a ~16% increase over the prior contracted rate of $509 (Exhibit 1). Although we had highlighted that there was some risk to this... More
Stifel on Exact Sciences (EXAS): 'CDLT Rate Up 16% for Cologuard Plus; A Stab At What That Means for FY25 ASP'
November 26, 2024 7:15 AM ESTStifel analyst Daniel Arias reiterated a Buy rating and $67.00 price target on Exact Sciences (NASDAQ: EXAS).
The analyst comments "CDLT Rate Gets A Boost. Today, CMS released the Clinical Laboratory Fee Schedule (CLFS) final determination with a $592 price tag for Cologuard Plus, representing a 16% price increase over the current version of Cologuard (which is reimbursed at $508 by Medicare). We caught up with EXAS tonight to inform our understanding of the Cologuard reimbursement trajectory if the company should choose the CDLT rate (which, in our minds, has been the less likely scenario when... More
Wolfe Research on Exact Sciences (EXAS): 'Cologuard Plus CLFS Rate Set At $592; Potential for ~$50MM Upside To '25 Revenue'
November 26, 2024 7:14 AM ESTWolfe Research analyst Doug Schenkel reiterated an Outperform rating and $70.00 price target on Exact Sciences (NASDAQ: EXAS)
The analyst comments "WHAT IS THE MODEL IMPACT? Cologuard Plus is launching in late Q1' 25/early Q2 '25, and we believe EXAS will be reimbursed $592 in Medicare FFS patients starting at... More
